Burden of Schistosomiasis and Soil-transmitted Helminth Infections in Schoolchildren in Banfora, … (NCT06973200) | Clinical Trial Compass
CompletedNot Applicable
Burden of Schistosomiasis and Soil-transmitted Helminth Infections in Schoolchildren in Banfora, Burkina Faso
Burkina Faso300 participantsStarted 2024-11-11
Plain-language summary
A cross-sectional study will be conducted among 300 schoolchildren in the Banfora region, including 120 in urban and 180 in rural areas, to assess the prevalence of schistosomiasis and soil-transmitted helminth infections. All children with S. mansoni and/or S. haematobium infections at enrolment will then be treated with dihydroartemisinin-piperaquine (DP) and followed up on days 1, 2, 3, 4, 28, and 42 to assess the efficacy and safety of DP. At the end of the study, all children (infected and uninfected) will receive praziquantel and albendazole according to national recommendations.
Who can participate
Age range
5 Years – 15 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 5 and 15 years;
* Resident in Banfora town for at least 6 months before the start of the study;
* Assent of the child (over 12 years of age);
* Informed consent from the child's parent or legal guardian.
Exclusion Criteria:
* Use of praziquantel and albendazole in the past 6 months;
* Use of Artemisinin-based combination therapies (ACTs) in the 3 weeks before study start-up;
* Known allergy to DP;
* Current episode of diarrhoea;
* Inability to provide stool and urine samples;
* Child absent on the day of the survey.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Prevalence of schistosomiasis and soil-transmitted helminth (STH) infections
Timeframe: January 2025
2
Intensity of S. mansoni and soil-transmitted helminth (STH) infections
Timeframe: January 2025
3
Intensity of S. haematobium infection
Timeframe: January 2025
4
Risk factors associated with schistosomiasis and soil-transmitted helminth infections
Timeframe: January 2025
Trial details
NCT IDNCT06973200
SponsorCentre MURAZ/Institut National de Santé Publique